James L Klosky1, Brianne Favaro2, Kelly R Peck3,4, Jessica L Simmons3, Kathryn M Russell3, Daniel M Green5,6, Melissa M Hudson5,6. 1. Department of Psychology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-2794, USA. james.klosky@stjude.org. 2. Department of Psychology, Winona State University, 175 W Mark St, Winona, MN, 55987, USA. 3. Department of Psychology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-2794, USA. 4. Department of Psychology, University of Mississippi, 205 Peabody, University, MS, 38677, USA. 5. Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-2794, USA. 6. Department of Epidemiology & Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-2794, USA.
Abstract
PURPOSE: Human papillomavirus (HPV) is a sexually transmitted infection and the cause of cervical and other cancers. Vaccination is available to protect against genital HPV and is recommended for individuals aged 9-26 years. This study aimed to estimate the prevalence of HPV vaccination among childhood cancer survivors and to identify factors associated with vaccine outcomes. METHODS: Young adult females with (n = 114; M age = 21.18 years, SD = 2.48) and without (n = 98; M age = 20.65 years, SD = 2.29) a childhood cancer history completed surveys querying HPV vaccination initiation/completion, as well as sociodemographic, medical, and health belief factors. Multivariable logistic regression was used to calculate odds ratios (ORs) and 95 % confidence intervals (CIs) for vaccine outcomes. RESULTS: Among survivors, 38.6 % (44/114) and 26.3 % (30/114) initiated or completed vaccination compared to 44.9 % (44/98) and 28.6 % (28/98) among controls, respectively. In the combined survivor/control group, physician recommendation (OR = 11.24, 95 % CI 3.15-40.14) and familial HPV communication (OR = 7.28, 95 % CI 1.89-28.05) associated with vaccine initiation. Perceptions of vaccine benefit associated with vaccine completion (OR = 10.55, 95 % CI 1.59-69.92), whereas perceptions of HPV-related severity associated with non-completion (OR = 0.14, 95 % CI 0.03-0.71). CONCLUSION: Despite their increased risk for HPV-related complication, a minority of childhood cancer survivors have initiated or completed HPV vaccination. Modifiable factors associated with vaccine outcomes were identified. IMPLICATIONS FOR CANCER SURVIVORS: HPV vaccination is a useful tool for cancer prevention in survivorship, and interventions to increase vaccine uptake are warranted.
PURPOSE:Human papillomavirus (HPV) is a sexually transmitted infection and the cause of cervical and other cancers. Vaccination is available to protect against genital HPV and is recommended for individuals aged 9-26 years. This study aimed to estimate the prevalence of HPV vaccination among childhood cancer survivors and to identify factors associated with vaccine outcomes. METHODS: Young adult females with (n = 114; M age = 21.18 years, SD = 2.48) and without (n = 98; M age = 20.65 years, SD = 2.29) a childhood cancer history completed surveys querying HPV vaccination initiation/completion, as well as sociodemographic, medical, and health belief factors. Multivariable logistic regression was used to calculate odds ratios (ORs) and 95 % confidence intervals (CIs) for vaccine outcomes. RESULTS: Among survivors, 38.6 % (44/114) and 26.3 % (30/114) initiated or completed vaccination compared to 44.9 % (44/98) and 28.6 % (28/98) among controls, respectively. In the combined survivor/control group, physician recommendation (OR = 11.24, 95 % CI 3.15-40.14) and familial HPV communication (OR = 7.28, 95 % CI 1.89-28.05) associated with vaccine initiation. Perceptions of vaccine benefit associated with vaccine completion (OR = 10.55, 95 % CI 1.59-69.92), whereas perceptions of HPV-related severity associated with non-completion (OR = 0.14, 95 % CI 0.03-0.71). CONCLUSION: Despite their increased risk for HPV-related complication, a minority of childhood cancer survivors have initiated or completed HPV vaccination. Modifiable factors associated with vaccine outcomes were identified. IMPLICATIONS FOR CANCER SURVIVORS: HPV vaccination is a useful tool for cancer prevention in survivorship, and interventions to increase vaccine uptake are warranted.
Entities:
Keywords:
Human papillomavirus; Oncology; Vaccination; Young adults
Authors: James L Klosky; Kathryn M Russell; Kristin E Canavera; Heather L Gammel; Jason R Hodges; Rebecca H Foster; Gilbert R Parra; Jessica L Simmons; Daniel M Green; Melissa M Hudson Journal: Cancer Prev Res (Phila) Date: 2013-08-27
Authors: S J Rolnick; E D Parker; J D Nordin; B D Hedblom; F Wei; T Kerby; J M Jackson; A L Crain; G Euler Journal: Vaccine Date: 2013-06-24 Impact factor: 3.641
Authors: Julia W Gargano; Edward J Wilkinson; Elizabeth R Unger; Martin Steinau; Meg Watson; Youjie Huang; Glenn Copeland; Wendy Cozen; Marc T Goodman; Claudia Hopenhayn; Charles F Lynch; Brenda Y Hernandez; Edward S Peters; Maria Sibug Saber; Christopher W Lyu; Lauren A Sands; Mona Saraiya Journal: J Low Genit Tract Dis Date: 2012-10 Impact factor: 1.925
Authors: Rohit P Ojha; Joseph E Tota; Tabatha N Offutt-Powell; James L Klosky; Ramkumar Ashokkumar; James G Gurney Journal: Ann Epidemiol Date: 2013-02-27 Impact factor: 3.797
Authors: Martin Steinau; Elizabeth R Unger; Brenda Y Hernandez; Marc T Goodman; Glenn Copeland; Claudia Hopenhayn; Wendy Cozen; Maria S Saber; Youjie Huang; Edward S Peters; Charles F Lynch; Edward J Wilkinson; Mangalathu S Rajeevan; Christopher Lyu; Mona Saraiya Journal: J Low Genit Tract Dis Date: 2013-10 Impact factor: 1.925
Authors: Neeraj K Arora; Roxanne E Jensen; Nadiyah Sulayman; Ann S Hamilton; Arnold L Potosky Journal: J Clin Oncol Date: 2013-09-23 Impact factor: 44.544
Authors: Rohit P Ojha; Joseph E Tota; Tabatha N Offutt-Powell; James L Klosky; Timothy D Minniear; Bradford E Jackson; James G Gurney Journal: PLoS One Date: 2013-08-05 Impact factor: 3.240
Authors: James L Klosky; Melissa M Hudson; Yanjun Chen; James A Connelly; Karen Wasilewski-Masker; Can-Lan Sun; Liton Francisco; Laura Gustafson; Kathryn M Russell; Gina Sabbatini; Jessica S Flynn; Jocelyn M York; Anna R Giuliano; Leslie L Robison; F Lennie Wong; Smita Bhatia; Wendy Landier Journal: J Clin Oncol Date: 2017-08-24 Impact factor: 44.544
Authors: Echo L Warner; Perla L Vaca Lopez; Deanna Kepka; Karely Mann; Heydon K Kaddas; Douglas Fair; Mark Fluchel; Elizabeth D Knackstedt; Samantha T Pannier; Laura Martel; Anne C Kirchhoff Journal: J Cancer Surviv Date: 2020-05-26 Impact factor: 4.442
Authors: Karely Mann; Yelena P Wu; Samantha T Pannier; Claire Hacking; Echo L Warner; Stephanie Rosen; Akanksha Acharya; Jennifer Wright; Cheryl Gerdy; Anne C Kirchhoff Journal: Support Care Cancer Date: 2020-05-21 Impact factor: 3.603